Goodbody Health (AQSE: GDBY) is pleased to announce that further to its news release dated June 10, 2022, the Company has mailed its proxy materials, with instructions on how to attend and vote, to its shareholders of record as of July 5, 2022 for its annual general and special meeting to be held on August 9, 2022 at 9 am (Pacific time) at The Blue Building, Stubbs Lane, Beckington, Frome, BA11 6TE, United Kingdom  (the “Meeting“).  The information circular dated July 8, 2022, forming part of the proxy materials, sets out full details of the Company’s intention to de-list from the Canadian Securities Exchange (the “De-Listing“) and to re-domicile the Company from the Province of British Columbia to Guernsey (the “Continuation“), subject to shareholder approval. The information circular and proxy materials will shortly be available at the Company’s website at www.goodbodyhealth.com.

Goodbody intends to retain its quote on the AQSE Growth Market in London and the OTCQB quote in the United States. Further announcements regarding the post-Continuation trading arrangements on the AQSE Growth Market will be made in due course.

Prior to the Continuation and the De-Listing, the Company intends to consolidate all of its issued and outstanding common shares on the basis of ten (10) pre-consolidation shares for one (1) post-consolidated share (the “Consolidation”).  The Company currently has 364,962,152 common shares issued and outstanding.  Following completion of the Consolidation, the Company would have approximately 36,496,215 common shares issued and outstanding.  The Company will also consolidate all warrants and Options to the same ratio. The Company currently has 36,603,461 options issued and outstanding.  Following completion of the Consolidation, the Company would have approximately 3,660,346 options issued and outstanding. The Company currently has 49,317,379 warrants issued and outstanding.  Following completion of the Consolidation, the Company would have approximately 4,931,737 warrants issued and outstanding. Any fractional common shares resulting from the Consolidation would be rounded to the nearest whole common share, with any fraction of 0.5 or above rounded up and any fraction of less than 0.5 rounded down.  Pursuant to the Company’s current articles, the Company’s board of directors can authorize the Consolidation by directors’ resolutions.  The Consolidation is subject to Canadian Securities Exchange approval.

The voting results from the Meeting regarding the Continuation will not affect the De-Listing or the Consolidation.

The Company’s proxy materials are also available on the Company’s SEDAR profile on www.sedar.com.

The directors of the Company accept responsibility for the contents of this announcement.